Oral high-dose methotrexate with citrovorum factor rescue in metastatic squamous cell carcinoma of the lung
- 1 February 1978
- Vol. 41 (2) , 400-402
- https://doi.org/10.1002/1097-0142(197802)41:2<400::aid-cncr2820410204>3.0.co;2-d
Abstract
Thirteen patients with metastatic squamous cell cancer of the lung were treated, in a nonrandomized study, with an oral high-dose methotrexate and citrovorum factor rescue regimen. There was some response and/or stabilization of disease for at least three months in six (46%) of 13 cases. The median survival time of the study group was double (365 vs. 180 days) that of a retrospectively matched control group. This suggests a possible therapeutic effect of this treatment program in metastatic squamous cell cancer of the lung.This publication has 5 references indexed in Scilit:
- Combination chemotherapy of advanced lung cancer.A randomized trialCancer, 1976
- Bacon (bleomycin, adriamycin, CCNU, oncovin and nitrogen mustard) in squamous lung cancer. Experience in fifty patientsCancer, 1976
- Phase I study of high doses of methotrexate with citrovorum factor in patients with lung cancerCancer, 1972
- Toxic and therapeutic effects of methotrexate-folinic acid (leucovorin) in advanced cancer and leukemiaWriting committee for the southeastern cancer study groupCancer, 1971
- Meaningful clinical classification of therapeutic responses to anticancer drugsClinical Pharmacology & Therapeutics, 1961